Latest News

Why Sonic Healthcare shares are drawing attention now Sonic Healthcare (ASX:SHL) has slipped to a decade low of A$18.88, with investors focused on how currency fluctuations, US tariffs, and rising labour costs are feeding into its current valuation. See our latest analysis for Sonic Healthcare. The recent dip to A$18.88 and current A$19.87 share price comes after a weaker 30 day share price return of 9.35% and a 1 year total shareholder return of 17.43%. This suggests that momentum has been...

National Storage REIT (ASX:NSR) has dispatched its scheme booklet for the proposed takeover by Brookfield and GIC. The booklet outlines key terms of the scheme, implications for investors, and the timeline for shareholder approval. This marks a material step in the acquisition process and sets out what existing securityholders are being asked to vote on. For investors watching ASX:NSR, the scheme booklet follows a period of strong longer term returns, with the stock up 34.0% over 1 year,...

Investors may be wondering whether Acadia Realty Trust is offering good value at its current price, or if the easier gains have already passed. The stock recently closed at US$20.37, with returns of 4.9% over the last week, a 1.6% decline over the last month, a 1.3% decline year to date, 14.3% over the last year, 74.9% over three years, and 23.6% over five years. Recent coverage has focused on Acadia as a retail focused REIT, with ongoing attention on how its portfolio and tenant mix...

If you are wondering whether Western Midstream Partners at around US$40.94 is still offering value, you are not alone. This article focuses on exactly that question. The unit price has moved by 2.1% over the last 30 days, with a 25.2% return over 1 year and a very large 217.2% return over 5 years. This naturally raises questions about how much value is already reflected in the current price. Recent news coverage has mainly centered on Western Midstream Partners as a key player in the US...

Wondering if Intercontinental Exchange at around US$161.97 is still a fair entry point or if the value story has already played out? This article focuses squarely on what the current price might imply. The stock has moved by 1.1% over the last 30 days and 5.6% over the past year, with a 56.5% return over 3 years and 44.1% over 5 years, which hints at a long track record that many investors will be weighing against today's valuation. Recent coverage has focused on Intercontinental Exchange as...

Investors may be wondering whether PACS Group at around US$35.97 is still offering value after its strong run, or if the easy gains are already behind it. The stock has moved 11.9% over the last 7 days and 5.3% over the last 30 days, while the 1 year return of 286.8% contrasts with a year to date return of a 9.0% decline. Recent attention on PACS Group has centered on its strong 1 year share price performance and the healthcare services segment it operates in. This has made the stock more...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

As European markets experience a wave of optimism amid hopes for a shorter Middle East conflict, the STOXX Europe 600 Index has seen notable gains alongside major indices in Germany, Italy, France, and the UK. In this context of fluctuating energy costs and inflationary pressures, identifying stocks that may be trading below their estimated value could provide investors with opportunities to capitalize on potential market inefficiencies.

While Mitchells & Butlers plc ( LON:MAB ) might not have the largest market cap around , it saw significant share price...

If you are wondering whether Tetra Tech's current share price offers good value or if you might be overpaying for quality, this article walks through the key valuation checks that matter most. The stock last closed at US$30.85, with a 0.7% decline over 7 days, an 8.1% decline over 30 days, and an 8.3% decline year to date. The 1 year, 3 year, and 5 year returns sit at 6.2%, 7.2%, and 16.9% respectively. Recent price movements are occurring against a backdrop of ongoing investor interest in...

Prairie Operating Co. reported past full-year 2025 results on March 30, 2026, showing revenue of US$241.65 million versus US$7.94 million a year earlier and moving from a net loss of US$40.91 million to net income of US$32.05 million, alongside detailed production disclosure. Management also issued production and earnings guidance for 2026, targeting average daily output of 25,500–27,500 Boe/d and net income of US$55 million to US$65 million, highlighting how operational scale now ties...

Technip Energies recently announced multiple project wins, including a contract from Long Son Petrochemicals to convert its Vietnamese steam cracker from naphtha to ethane and new authorizations from Commonwealth LNG to advance a 9.5 Mtpa LNG export facility in Louisiana using its modular SnapLNG solution. These awards highlight Technip Energies’ proprietary ethylene and LNG technologies as key enablers for feedstock flexibility, energy efficiency and lower-carbon petrochemical and gas...

BNP Paribas (ENXTPA:BNP) has expanded its senior leadership team across emerging markets. The bank appointed a new head of Gulf Debt Capital Markets, who will relocate to Abu Dhabi. BNP Paribas also hired Abhishek Joshi, previously head of UBS’s ECM business in India, to grow its investment banking franchise there. For you as an investor, these moves sit at the intersection of investment banking, debt markets and equity capital markets activity. The Middle East and India have been active...

Akari Therapeutics has entered a partnership with WuXi XDC Cayman (SEHK:2268) to support development of Akari’s PH1 payload and AKTX-101 program for metastatic urothelial cancer, further linking WuXi XDC to next generation ADC platforms. See our latest analysis for WuXi XDC Cayman. Investors appear to be weighing WuXi XDC’s new ADC partnership against a mixed share price pattern. The 30 day share price return of 3.64% contrasts with a 90 day share price return decline of 13.75% and a 1 year...

Wondering whether LANXESS at €17.85 is offering value or just another value trap? This breakdown is designed to help you make sense of the current price. The share price has moved 0.2% over the past week and 31.7% over the last 30 days, while 1 year returns of negative 22.0% and 3 and 5 year returns of negative 48.6% and negative 68.4% highlight a tougher longer term experience for shareholders. Recent coverage has focused on LANXESS as investors reassess chemicals exposure and individual...

Sembcorp Industries has appointed BW Group chairman Andreas Sohmen-Pao as non-executive and independent chairman, and veteran auditor Steven Phan Swee Kim as a new independent director, following the retirement of current chairman Tow Heng Tan and audit committee chairman Yap Chee Keong after their multi-year tenures. These board changes bring in deep maritime, decarbonisation and audit expertise at a time when Sembcorp is reshaping its portfolio around energy transition and risk...

Wondering if Oncolytics Biotech at US$1.04 is priced for its potential or already running ahead of itself? This article walks through what the numbers are actually saying about value. The stock shows mixed return figures, with a 7 day return of 8.3%, 30 day return of 2.0%, year to date return of 5.7%, a 1 year return of 108.0%, a 3 year return of 11.9% decline, and a 5 year return of 64.5% decline that some investors may see as a reset in expectations. Recent attention around Oncolytics...

BridgeBio Pharma (NasdaqGS:BBIO) reported long term data for acoramidis (Attruby) in transthyretin amyloid cardiomyopathy, showing sustained efficacy, safety and quality of life outcomes over several years. The company highlighted the role of early and continuous treatment for ATTR-CM patients, citing ongoing unmet medical needs with existing options. BridgeBio submitted a New Drug Application to the US FDA for BBP-418, supported by Phase 3 data in limb-girdle muscular dystrophy type...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Insiders who bought R19.1b worth of Vunani Limited ( JSE:VUN ) stock in the last year have seen some of their losses...

The market shrugged off Safilo Group S.p.A.'s ( BIT:SFL ) solid earnings report. We did some digging and believe...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

As tensions in the Middle East and energy market volatility continue to influence global markets, Asian equities are navigating a complex landscape of geopolitical risks and economic uncertainties. Amid these challenges, investors often seek stocks that may be undervalued relative to their intrinsic worth, offering potential opportunities for those who prioritize fundamental analysis over short-term market fluctuations.